Brief: Ifinatamab Deruxtecan Biologics License Application For Patients With Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawn
25/09/2026 22:45
BRIEF-Ifinatamab Deruxtecan Biologics License Application For Patients With Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawn Sept 26 (Reuters) - Merck & Co Inc MRK.N:
IFINATAMAB DERUXTECAN BIOLOGICS LICENSE APPLICATION FOR CERTAIN PATIENTS WITH PREVIOUSLY TREATED EXTENSIVE-STAGE SMALL CELL LUNG CANCER VOLUNTARILY WITHDRAWN
MERCK & CO - WITHDRAWAL BASED ON FDA DISCUSSIONS; PHASE 2 DATA DO NOT SATISFY APPROVAL REQUIREMENTS
MERCK & CO - PATIENT ENROLLMENT CONTINUES IN IDEATE-LUNG02 PHASE 3 TRIAL FOR IFINATAMAB DERUXTECAN
MERCK & CO - TWO ADDITIONAL PHASE 3 TRIALS UNDERWAY FOR IFINATAMAB DERUXTECAN IN CRPC AND ESCC
MERCK & CO - DAIICHI SANKYO AND MERCK WITHDRAW BLA FOR IFINATAMAB DERUXTECAN IN ES-SCLC IN U.S.
Source text: ID:nBw2fFVpKa
Further company coverage: MRK.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Merck & Co
See all newsBrief: European Commission Approves Keytruda Plus Padcev As Perioperative Treatment For Adults With Resectable Muscle-Invasive Bladder Cancer
US STOCKS-Dow leads Wall Street higher, investors focus on healthcare stocks
Moderna recoups part of losses as BofA raises PO ahead of key cancer vaccine readout
Live Markets: Dot-com deja vu? Why Goldman Sachs is calling time on the momentum trade
Factbox: Pharma sector doubles down on AI to slash costs, timelines